Testing early stopping of MRSA antibiotics for pneumonia
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether a simple nasal swab can help doctors safely stop unnecessary MRSA antibiotics sooner in people with pneumonia. If the swab shows no MRSA, the antibiotic can be stopped early, which may reduce side effects and drug resistance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are currently hospitalized at the Azienda Consorziale Policlinico di Bari in Italy
- You have been diagnosed with pneumonia (community-acquired, hospital-acquired, or ventilator-associated)
- Your doctor has decided to start an antibiotic covering MRSA as a first treatment
- You can be enrolled within 48 hours of starting that antibiotic
- You do not have a weak immune system, chronic airway infection, or suspected MRSA infection outside the lungs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether elderly patients hospitalized with a viral lower respiratory infection can safely stop antibiotics early. It aims to reduce unnecessary antibiotic use and side effects.
This study tests ways to get rid of MRSA bacteria in the body when it is “complicated,” such as having MRSA outside the nose or an ongoing MRSA infection. It may help reduce future MRSA problems or infections by lowering how long the bacteria stay in your body.
This trial tests whether using a rapid test to find the exact bacteria causing your pneumonia can help doctors choose the right antibiotics faster, which might improve your recovery. The study compares this approach to usual care in patients on ventilators.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) to see if they work better than other treatments for people with pneumonia that started in the hospital or from a breathing machine. If you qualify, this study might offer you a new treatment option.
This study looks at how antibiotics affect MRSA (a type of staph infection) in the noses of hospitalized children. It may help doctors better understand MRSA to improve treatment.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
Hear when a new Pneumonia, Bacterial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.